Henagliflozin for advanced chronic kidney disease
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a drug called henagliflozin (a type of SGLT2 inhibitor) to see if it can slow kidney decline in people with advanced chronic kidney disease who are not yet on dialysis. You may receive the drug or a placebo, and the trial will follow your kidney health over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 or older
- eGFR (a kidney function test result) between 10 and 30, which means your kidneys are working at a reduced level but you are not on dialysis
- A urine test showing protein in the urine (UACR between 150 and 5000 mg/g)
- If your eGFR is 20-30, you must be taking an ACE inhibitor or ARB (blood pressure medicines that protect the kidneys) for at least 4 weeks, unless you are intolerant
- Not planning to start dialysis within the next month
- Willing to take the study drug or placebo, attend follow-up visits, and be monitored for at least 2 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
This trial tests a medicine called empagliflozin (usually used for diabetes) to see if it can help people with very advanced kidney disease and diabetes. The study will check if this drug can slow down further kidney damage and improve overall kidney health.
This trial tests if canagliflozin, a diabetes medication, can help people with very advanced kidney disease or who recently started dialysis. It uses MRI scans to see how the drug affects the heart and kidneys.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This study tests whether a daily medication can slow down kidney damage in people with type 1 diabetes who already have some kidney problems. It may help protect your kidneys from getting worse.
This study tests whether the drug canagliflozin (a type of diabetes medicine) is safe and works in people on dialysis. It may help improve fluid balance or blood sugar control in hemodialysis patients.
Hear when a new Chronic Kidney Disease Stage 4 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.